Are long-chain methotrexate polyglutamate levels the reason for LD-MTX related adverse events in inflammatory arthritis?

Click to increase image sizeClick to decrease image size

Declaration of Conflicting Interests

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Author Contribution

A. Sandhu worked on the determination of methotrexate polyglutamate levels in his doctoral study under the direct guidance of V. Dhir. He brings the idea along with P. Kaur and O.M. Bhat. The first draft was written by A. Sandhu. All the authors have approved the final version. All the authors agree to be accountable for all aspects of this editorial article.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose

Additional information

Funding

This paper was not funded